Results 201 to 210 of about 728,357 (259)
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou +7 more
wiley +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
European Journal of Nuclear Medicine and Molecular Imaging, 1997
The placebo effect will have a growing importance in the field of nuclear medicine as the potentials for palliative therapy with internal sources are realized. It is important for nuclear medicine physicians and their colleagues to be familiar with the role of placebo responses in clinical trials, especially when such trials involve the subjective ...
Mary Jane Heeg +2 more
openaire +2 more sources
The placebo effect will have a growing importance in the field of nuclear medicine as the potentials for palliative therapy with internal sources are realized. It is important for nuclear medicine physicians and their colleagues to be familiar with the role of placebo responses in clinical trials, especially when such trials involve the subjective ...
Mary Jane Heeg +2 more
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1985
To the Editor.— Drs Kramer and Shapiro 1 give some valuable guidelines to improving the quality of research in their article, "Scientific Challenges in the Application of Randomized Trials," in the Nov 16, 1984, issue ofThe Journal. However, I'm afraid they perpetuate some of the misunderstandings concerning the nature of the placebo effect and its ...
openaire +3 more sources
To the Editor.— Drs Kramer and Shapiro 1 give some valuable guidelines to improving the quality of research in their article, "Scientific Challenges in the Application of Randomized Trials," in the Nov 16, 1984, issue ofThe Journal. However, I'm afraid they perpetuate some of the misunderstandings concerning the nature of the placebo effect and its ...
openaire +3 more sources
Journal of Allergy and Clinical Immunology, 1986
Historically the term placebo harks back to the 116th psalm in the Hebrew bible. The ninth verse of this psalm begins with the word “et-ha-lech” (I shall walk), which was strangely translated into the Septuagint Greek as “euarestiso” and then into its Vulgate Latin equivalent of “placebo,” the first-person singular future tense of the verb meaning to ...
openaire +3 more sources
Historically the term placebo harks back to the 116th psalm in the Hebrew bible. The ninth verse of this psalm begins with the word “et-ha-lech” (I shall walk), which was strangely translated into the Septuagint Greek as “euarestiso” and then into its Vulgate Latin equivalent of “placebo,” the first-person singular future tense of the verb meaning to ...
openaire +3 more sources
7. placebos and the placebo effect [PDF]
, 2015 SummaryIn addition to the actual pharmacological effect of a drug, its efficacy depends on a number of non-specific factors globally termed the placebo effect. To distinguish the pharmacological effect from the non-specific effect it may be justified to compare a supposedly active drug to a placebo, a “pseudo-drug” identical in appearance but ...
P. Simon +3 more
openaire +1 more source